Adjusting the Risk Calculation for Biopsy-Detectable Prostate Cancer
Researchers sought to demonstrate how recalibration of risk stratification tools can improve accuracy and clinical decision making.
Researchers sought to demonstrate how recalibration of risk stratification tools can improve accuracy and clinical decision making.
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
A retrospective analysis revealed that opening up access to health care eliminated the gap in timeliness to care between white and black patients.
While 1 in 3 trials on cancer treatment excluded patients with cardiovascular disease, definitions and reasoning for exclusion were not well documented.
Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.
AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
The use of rituximab for autoimmune thrombotic thrombocytopenic purpura did not significantly reduce acute iTTP relapses.
Lay health workers used phone calls to assess symptoms on a weekly basis for high-risk patients and on a monthly basis for low-risk patients.
Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.